Last Updated: 8/19
Share or print this information to talk to your doctor about this trial.
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).
18 to 65
Inclusion Criteria for Cohort A and B:
oral body temperature between 35.0-37.5 °C systolic blood pressure, 80-170 mm Hg diastolic blood pressure, 50-105 mm Hg pulse rate, 45 - 100 bpm
Inclusion Criteria for Cohort A:
Inclusion Criteria for Cohort B:
Exclusion Criteria for Cohort A and B:
Novartis Investigative Site
Iowa City, Iowa 52242
Ranica, BG 24020
L Hospitalet De Llobregat, Barcelona 08907
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below.
1-888-669-6682 | email@example.com +41613241111
View complete study information on ClinicalTrials.gov
Thank you for visiting WeC3GTM
You are now leaving the WeC3G.com website and being directed to a third-party website. Achillion Pharmaceuticals, Inc. is not responsible for the content of the site you are about to visit.
Would you like to continue?
Continued use of this site indicates you have accepted this policy.